NCT03588091 2025-08-22
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
Clinical Trials
8 trialsNCT07115095 2025-08-11
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
Shaanxi Provincial Cancer Hospital
Phase NA Completed
NCT03330561 2024-04-22
PRS-343 in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
Phase 1 Completed
NCT03650348 2024-04-22
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
Phase 1 Completed
NCT06107790 2023-10-30
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 3 Completed
NCT03953833 2023-09-14
B003-101
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1 Completed
NCT03281824 2022-01-18
Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients
Alteogen, Inc.
Phase 1 Completed
NCT02135159 2017-08-14
BIRTH
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1 Completed